Also known as: Orbital Therapeutics
Orbital Therapeutics is an RNA medicines company focused on building a platform at the intersection of RNA delivery technology, data science, and automation. It describes an initial therapeutic focus spanning vaccines, immunomodulation, protein replacement, and regenerative medicine. The company launched in 2022 and is based in Cambridge, Massachusetts.
Bristol Myers Squibb's growth portfolio increased 17% in 2025, partially offsetting a 15% decline in legacy products facing generic competition. The company's stock gained 11.4% in the past month on strong fourth-quarter results.
Next-generation in vivo CAR-T therapy enables cancer treatment with a single injection, while new Texas legislation and community-based delivery models expand patient access to this advanced cellular therapy.
